AR069966A1 - Derivado de (gamma)-lactona de esteroide del acido 17-hidroxi-19-nor-21-carboxilico, su uso y el medicamento que lo contiene - Google Patents
Derivado de (gamma)-lactona de esteroide del acido 17-hidroxi-19-nor-21-carboxilico, su uso y el medicamento que lo contieneInfo
- Publication number
- AR069966A1 AR069966A1 ARP080105703A ARP080105703A AR069966A1 AR 069966 A1 AR069966 A1 AR 069966A1 AR P080105703 A ARP080105703 A AR P080105703A AR P080105703 A ARP080105703 A AR P080105703A AR 069966 A1 AR069966 A1 AR 069966A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- alkyl
- group
- gamma
- alkynyl
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 9
- 239000001257 hydrogen Substances 0.000 abstract 9
- 150000002431 hydrogen Chemical group 0.000 abstract 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 4
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- -1 2-carboxyvinyl Chemical group 0.000 abstract 1
- 230000001548 androgenic effect Effects 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000003152 gestagenic effect Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J19/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Cosmetics (AREA)
Abstract
Uso de estos derivados para la preparacion de un medicamento para la contracepcion oral y para el tratamiento de trastornos pre, peri y posmenopáusicos, así como a medicamentos que contienen tales derivados. Los derivados de la solicitud presentan un efecto gestagénico y en casos preferidos además un efecto antimineralcorticoide y neutro a ligeramente androgénico. Reivindicacion 1: Derivado de gamma-lactona del esteroide del ácido 17-hidroxi-19-nor-21-carboxílico con la siguiente formula química (1) caracterizado porque Z se selecciona del grupo que comprende oxígeno, dos átomos de hidrogeno, NOR' y NNHSO2R', donde R' es hidrogeno, alquilo C1-10, arilo o aralquilo C7-20, R4 se selecciona del grupo que comprende hidrogeno y halogeno, donde además R6a, R6b se seleccionan de manera independiente del grupo que comprende hidrogeno, alquilo C1-10, alquenilo C2-10 y alquinilo C2-10, o forman juntos metileno o 1,2-etandiilo, y R7 se selecciona del grupo que comprende hidrogeno, alquilo C1-10, cicloalquilo C3-6, alquenilo C2-10 y alquinilo C2-10, o R6a, R7 son juntos un átomo de oxígeno o metileno, o se suprimen al formarse un enlace doble entre C6 y C7, y R6b se selecciona del grupo que comprende hidrogeno, alquilo C1-10, alquenilo C2-10 y alquinilo C2-10, donde además R15 es hidrogeno, y R16a, R16b se seleccionan de manera independiente del grupo que comprende hidrogeno y alquiloC1-10, o forman juntos metileno o 1,2-etandiilo, o R15, R16a son juntos un átomo de oxígeno, o se suprimen al formarse un enlace doble entre C15 y C16, y R16bes hidrogeno o alquilo C1-10, R18 es hidrogeno o alquilo C1-3, y también sus solvatos, hidratos, estereoisomeros y sales, con excepcion de la gamma-lactona de 17alfa-(2-carboxivinil)-17beta-hidroxi-19-nor-androst-4-en-3-ona.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007063503A DE102007063503A1 (de) | 2007-12-29 | 2007-12-29 | 17-Hydroxy-19-nor-21-carbonsäure-Steroid y-Lacton-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069966A1 true AR069966A1 (es) | 2010-03-03 |
Family
ID=40481980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105703A AR069966A1 (es) | 2007-12-29 | 2008-12-23 | Derivado de (gamma)-lactona de esteroide del acido 17-hidroxi-19-nor-21-carboxilico, su uso y el medicamento que lo contiene |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8937058B2 (es) |
| EP (1) | EP2238151A1 (es) |
| JP (1) | JP5600068B2 (es) |
| KR (1) | KR20100102688A (es) |
| CN (1) | CN101910190A (es) |
| AR (1) | AR069966A1 (es) |
| AU (1) | AU2008342910A1 (es) |
| BR (1) | BRPI0821922A2 (es) |
| CA (1) | CA2710491C (es) |
| CL (1) | CL2008003918A1 (es) |
| CO (1) | CO6300845A2 (es) |
| CR (1) | CR11545A (es) |
| DE (1) | DE102007063503A1 (es) |
| DO (1) | DOP2010000198A (es) |
| EC (1) | ECSP10010318A (es) |
| IL (1) | IL206379A0 (es) |
| PA (1) | PA8809701A1 (es) |
| PE (1) | PE20091362A1 (es) |
| TW (1) | TW200940073A (es) |
| UY (1) | UY31584A1 (es) |
| WO (1) | WO2009083266A1 (es) |
| ZA (1) | ZA201005396B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007063503A1 (de) | 2007-12-29 | 2009-07-02 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-19-nor-21-carbonsäure-Steroid y-Lacton-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| WO2012059594A1 (en) | 2010-11-04 | 2012-05-10 | Bayer Pharma Aktiengesellschaft | Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2918463A (en) | 1958-06-12 | 1959-12-22 | Searle & Co | 17-carboxyalkylated 17-hydroxy-19-norandrosten-3-ones |
| US3194803A (en) * | 1960-04-28 | 1965-07-13 | Searle & Co | Process and intermediates for the manufacture of 3-keto-delta4, 6 steroids |
| US3254074A (en) * | 1962-04-25 | 1966-05-31 | Merck & Co Inc | Spiroxenones |
| DE1183500B (de) | 1962-10-12 | 1964-12-17 | Schering Ag | Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe |
| US3705179A (en) | 1971-03-15 | 1972-12-05 | American Home Prod | Antiandrogenic steroids |
| US3764596A (en) * | 1971-06-22 | 1973-10-09 | Sandoz Ag | 17-dihydrofuranyl-substituted steroids |
| NL7701384A (nl) | 1977-02-10 | 1978-08-14 | Akzo Nv | Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks. |
| DE2922500A1 (de) | 1979-05-31 | 1980-12-04 | Schering Ag | 6 beta .7 beta |
| DE3022337A1 (de) * | 1980-06-11 | 1982-01-07 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen |
| JPS59139400A (ja) * | 1983-01-31 | 1984-08-10 | Shionogi & Co Ltd | 抗アルドステロン活性ステロイド誘導体 |
| DE3402329A1 (de) | 1984-01-20 | 1985-08-01 | Schering AG, 1000 Berlin und 4709 Bergkamen | 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
| DE3410880A1 (de) * | 1984-03-21 | 1985-10-03 | Schering AG, Berlin und Bergkamen, 1000 Berlin | 17-substituierte estradiene und estratriene |
| DE3426771C2 (de) * | 1984-07-07 | 1997-03-20 | Schering Ag | 13alpha-Methylgonane, deren Herstellung und Verwendung |
| DE4232521A1 (de) * | 1992-09-22 | 1994-03-24 | Schering Ag | Gestagen wirksame 4,5;11,12-Estradiene, Verfahren zu ihrer Herstellung, diese Estradiene enthaltende Arzneimittel sowie deren Verwendung zur Herstellung von Arzneimitteln |
| DE4447401A1 (de) * | 1994-12-23 | 1996-07-04 | Schering Ag | 14,17-C¶2¶-überbrückte Steroide |
| DE19651000A1 (de) | 1996-12-01 | 1998-06-04 | Schering Ag | Oxyiminopregnancarbolactone |
| DE102004063864A1 (de) | 2004-12-30 | 2006-07-13 | Schering Ag | 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate |
| DE102007063503A1 (de) | 2007-12-29 | 2009-07-02 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-19-nor-21-carbonsäure-Steroid y-Lacton-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
-
2007
- 2007-12-29 DE DE102007063503A patent/DE102007063503A1/de not_active Withdrawn
-
2008
- 2008-12-22 TW TW097150069A patent/TW200940073A/zh unknown
- 2008-12-23 EP EP08868806A patent/EP2238151A1/de not_active Withdrawn
- 2008-12-23 US US12/810,991 patent/US8937058B2/en not_active Expired - Fee Related
- 2008-12-23 AR ARP080105703A patent/AR069966A1/es unknown
- 2008-12-23 KR KR1020107016941A patent/KR20100102688A/ko not_active Withdrawn
- 2008-12-23 CA CA2710491A patent/CA2710491C/en not_active Expired - Fee Related
- 2008-12-23 JP JP2010540078A patent/JP5600068B2/ja not_active Expired - Fee Related
- 2008-12-23 BR BRPI0821922-2A patent/BRPI0821922A2/pt not_active IP Right Cessation
- 2008-12-23 CN CN200880123431XA patent/CN101910190A/zh active Pending
- 2008-12-23 PA PA20088809701A patent/PA8809701A1/es unknown
- 2008-12-23 AU AU2008342910A patent/AU2008342910A1/en not_active Abandoned
- 2008-12-23 WO PCT/EP2008/011159 patent/WO2009083266A1/de not_active Ceased
- 2008-12-26 UY UY31584A patent/UY31584A1/es not_active Application Discontinuation
- 2008-12-29 PE PE2008002191A patent/PE20091362A1/es not_active Application Discontinuation
- 2008-12-29 CL CL2008003918A patent/CL2008003918A1/es unknown
-
2010
- 2010-06-15 IL IL206379A patent/IL206379A0/en unknown
- 2010-06-29 CO CO10078679A patent/CO6300845A2/es not_active Application Discontinuation
- 2010-06-29 CR CR11545A patent/CR11545A/es not_active Application Discontinuation
- 2010-06-29 EC EC2010010318A patent/ECSP10010318A/es unknown
- 2010-06-29 DO DO2010000198A patent/DOP2010000198A/es unknown
- 2010-07-28 ZA ZA2010/05396A patent/ZA201005396B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011507924A (ja) | 2011-03-10 |
| AU2008342910A1 (en) | 2009-07-09 |
| ZA201005396B (en) | 2012-01-25 |
| EP2238151A1 (de) | 2010-10-13 |
| CA2710491A1 (en) | 2009-07-09 |
| PA8809701A1 (es) | 2009-07-23 |
| KR20100102688A (ko) | 2010-09-24 |
| US20110021472A1 (en) | 2011-01-27 |
| IL206379A0 (en) | 2010-12-30 |
| CA2710491C (en) | 2015-11-03 |
| TW200940073A (en) | 2009-10-01 |
| BRPI0821922A2 (pt) | 2015-06-16 |
| CN101910190A (zh) | 2010-12-08 |
| JP5600068B2 (ja) | 2014-10-01 |
| US8937058B2 (en) | 2015-01-20 |
| WO2009083266A1 (de) | 2009-07-09 |
| UY31584A1 (es) | 2009-08-03 |
| CL2008003918A1 (es) | 2010-01-15 |
| CO6300845A2 (es) | 2011-07-21 |
| PE20091362A1 (es) | 2009-10-15 |
| CR11545A (es) | 2010-08-27 |
| DE102007063503A1 (de) | 2009-07-02 |
| ECSP10010318A (es) | 2010-08-31 |
| DOP2010000198A (es) | 2010-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501679A1 (en) | 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators | |
| MX2021000375A (es) | Degradadores selectivos del receptor de estrogeno. | |
| AR066970A1 (es) | Derivado de 17 beta-ciano-18a-homo-19-nor-androst-4- eno, su uso y medicamento que lo contiene | |
| PA8783401A1 (es) | Derivados de piperidina/piperazina | |
| BRPI0606895A2 (pt) | novos compostos com efeito terapêutico | |
| BR112018010107A2 (pt) | composição farmacêutica para o tratamento ou prevenção de nash | |
| PE20170084A1 (es) | Derivados de 17-hidroxi-17-pentafluoroetil-estra-4-9(10)-dien-11-arilo como antagonistas de progesterona y procedimientos para su preparacion | |
| BR112018069712A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a. | |
| AR067454A1 (es) | Derivados de indano- amina, su preparacion y uso como medicamentos | |
| AR069966A1 (es) | Derivado de (gamma)-lactona de esteroide del acido 17-hidroxi-19-nor-21-carboxilico, su uso y el medicamento que lo contiene | |
| AR069963A1 (es) | Derivado 15, 16-metilen-17- (1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene | |
| AR069965A1 (es) | Derivado de (gamma)-lactona de esteroide de acido 15, 16 -metilen-17-hidroxi-19-nor-21-carboxilico, su uso para preparar un medicamento que lo contiene y medicamento que contiene al compuesto | |
| AR066971A1 (es) | Derivado de 17beta-ciano-19-nor-androst-4-eno- su uso y medicamento que lo contiene | |
| AR069964A1 (es) | Derivado de 17-(1'-propenil) -17-3' -oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen | |
| MX2010007929A (es) | Imidazolinilmetil aril sulfonamidas novedosas. | |
| UA98834C2 (ru) | 19-НОР-СТЕРОИДНЫЕ ПРОИЗВОДНЫЕ С 15α,16α-МЕТИЛЕНОВОЙ ГРУППОЙ И НАСЫЩЕННЫМ 17,17-СПИРОЛАКТОНОВЫМ КОЛЬЦОМ, ИХ ПРИМЕНЕНИЕ И ЛЕКАРСТВЕННОЕ СРЕДСТВО, КОТОРОЕ СОДЕРЖИТ ЭТИ ПРОИЗВОДНЫЕ | |
| CU20100141A7 (es) | Derivados de ganma-lactona del esteroide del ácido 17-hidroxi-19-nor-21-carboxílico, su uso y el medicamento que lo contiene | |
| RU2010100337A (ru) | ПРОИЗВОДНОЕ 17β-ЦИАНО-19-АНДРОСТ-4-ЕНА, ЕГО ПРИМЕНЕНИЕ И ЛЕКАРСТВЕННЫЕ СРЕДСТВА, КОТОРЫЕ ВКЛЮЧАЮТ ПРОИЗВОДНОЕ | |
| CU20100139A7 (es) | Derivados de y-lactona de esteroide de ácido 15,16-metilen-17-hidroxi-19-nor-21-carboxílico, su uso y medicamentos que contienen tal derivado | |
| CU20100138A7 (es) | Derivados de 17-(1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen | |
| MX2010007928A (es) | Imidazolinilmetil aril sulfonamidas novedosas. | |
| IL206763A0 (en) | Novel imidazolinylmethyl aryl sulfonamides | |
| TH104140A (th) | อนุพันธ์ 17-ไฮดรอกซี-19-นอร์-21-คาร์บอกซิลิคแอซิด-สเตอรอยด์ แกมมา-แลคโตน การใช้สารนี้และผลิตภัณฑ์ทางยาที่มีอนุพันธ์นี้อยู่ด้วย | |
| AR023683A1 (es) | Compuestos benzopiranos con accion antagonista de los leucotrienos, procedimiento para su preparacion y utilizacion en la preparacion de un medicamento. | |
| GB928493A (en) | Steroid compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |